Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2015. The report details a blocklisting application submitted to the Financial Conduct Authority and the London Stock Exchange Plc regarding the admission of new ordinary shares to the Official List.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice regarding share issuance rather than a financial results report.
Material Changes
The material change disclosed is the reservation of 21,539,000 Ordinary shares of 25p each under block listings. These shares are reserved for issuance pursuant to employee share schemes and will rank pari passu with existing ordinary shares upon issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the administrative process of listing shares for the following schemes:
- GlaxoSmithKline Share Option Plan - Ordinary shares: 5,000,000
- GlaxoSmithKline Share Option Plan - ADS: 13,000,000
- GlaxoSmithKline plc Sharesave plan 2012: 3,539,000
Investor Verification Points
- Confirm the total number of shares reserved (21,539,000) and their allocation across specific employee plans.
- Verify the admission status of these shares to the Official List with the London Stock Exchange.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly reports for financial metrics.